MedWatch

A part of Watch Media

Novo Nordisk waves goodbye to VP in charge of device development

Kenneth Strømdahl has left Novo Nordisk after 17 year with the company. The past few years, he was responsible for the pharmaceutical company's Devices and Delivery Solutions division, where he oversaw more than 300 employees and the development of devices helping patients handle their diseases.

Photo: Novo Nordisk / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

After 17 years in several positions at Novo Nordisk, Kenneth Strømdahl is off to pastures new.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Foto: Tyrone Siu/Reuters/Ritzau Scanpix

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

  1. Board chair at Coloplast and Lundbeck warns against large pay rises
  2. Ellab slapped with customs fine over US imports
  3. China approves Y-mabs drug
  4. CEO gets "taste of own medicine" by participating in vaccine trial
  5. FDA approves Covid-19 jabs as boosters for infants
  6. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  7. FDA approves new sensor for insulin pens
  8. Full house for Ambu – all products live up to new EU requirements
  9. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  10. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  11. New majority owner makes several board appointments at hearing firm
  12. FDA awards Pfizer's RSV vaccine candidate priority review status
  13. More countries back EU Commission investigation into potential Oticon sale
  14. Nobel Prize winner: "Good research is driven by curiosity"
  15. Forward Pharma's last hope in protracted Biogen battle extinguished

See all

Job

See all jobs

See all jobs